SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as investors weigh its attractive dividend and discounted valuation against significant headwinds in broadband subscriber growth and rising competition. While some in the community view the stock as a long-term income play bolstered by its profitable media assets, others remain skeptical, pointing to the declining cable business and ongoing concerns over the company's debt load.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing heightened scrutiny as it lingers near multi-year lows, sparking a heated debate between investors viewing current levels as a rare accumulation opportunity and others fearing the project has lost its competitive edge. The community remains deeply divided over whether the network's underlying technological adoption and enterprise partnerships will eventually overcome the downward price trend.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a significant surge in trading volume and bullish sentiment surrounding the company's QNX software platform, which is increasingly positioned as a foundational technology for Physical AI and autonomous systems. The community is actively discussing upcoming earnings, potential new design wins, and the long-term growth potential of BlackBerry's software-defined vehicle strategy despite historical skepticism from some market analysts.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is experiencing significant community attention as investors weigh the impact of shifting interest rate expectations against a flurry of recent M&A activity and positive clinical trial results within the sector. Discussions are currently centered on identifying potential buyout targets and navigating sector-wide volatility, with many community members focusing on managing risk through careful stock selection and long-term thesis validation.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is trending as investors debate the sustainability of the sector's recent rally, with the community actively discussing potential overbought signals and the necessity of portfolio rotation into defensive assets. Sentiment is split between those viewing recent pullbacks as buying opportunities for high-quality tech infrastructure and those hedging against broader market volatility and structural exhaustion.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is trending as investors monitor anticipation surrounding upcoming earnings and the potential impact of major defense contracts, including the ongoing competition for the Next Generation Short Range Interceptor (NGSRI) program. The community is actively discussing the company's strategic positioning within the U.S. defense supply chain, particularly regarding its proprietary BlackDiamond infrared optics technology as a solution for germanium supply constraints.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The biotechnology sector is experiencing a significant surge as investors rotate into the space, fueled by a high frequency of M&A activity and positive clinical data readouts. The community is actively debating the sustainability of this rally, with many focusing on whether recent acquisitions and therapeutic breakthroughs signal the beginning of a long-term recovery for small-cap biotech stocks.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARK Innovation ETF is trending as investors scrutinize Cathie Woods active portfolio management, particularly her recent rotation between semiconductor giants and emerging AI-focused ventures. The community is sharply divided, debating whether these frequent trades reflect high-conviction positioning for future innovation or a struggle to maintain performance against broader market benchmarks.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing high volatility as investors speculate on a short squeeze, driven by its low float and intense social media focus on its post-quantum cybersecurity narrative. The community is actively debating the stock's long-term viability versus its potential as a momentum-driven liquidity trade, while monitoring key technical levels and partnership headlines as catalysts for a potential breakout.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is currently attracting significant investor attention as the company aligns with the FDA on a potential regulatory path for its wet AMD treatment, AXPAXLI. The community is actively debating the stock's future, weighing the significance of successful clinical data against concerns regarding potential competition and the ongoing legal dispute with EyePoint Pharmaceuticals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times...

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Companys name...

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +16.67% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs

Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.read more...

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including...

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its...

Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia...

Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.50
Prev Close	$3.37
Open	$3.42
Dividend Yield	0.00%
50-Day Moving Average	$4.11
Beta	1.33
Avg. Volume	1.15M
PE Ratio	16.03

52-Week High	$14.69
52-Week Low	$3.35
Market Capitalization	$278.76M
EPS (Annual)	$0.2034
Price to Book	3.38
Revenue Per Employee	$1.11M

NAGENiagen Bioscience Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NAGE News